Statins amplify TLR-induced responses in microglia via inhibition of cholesterol biosynthesis

GLIA

Volumn 60, Issue 1, 2012, Pages 43-52

  Van Der Putten, Céline ^a   Kuipers, Hedwich F ^b   Zuiderwijk Sick, Ella A ^a   Van Straalen, Linda ^a   Kondova, Ivanela ^a   Van Den Elsen, Peter J ^c,d   Bajramovic, Jeffrey J ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b STANFORD UNIVERSITY   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cell activation; Inflammation; Monocytes macrophages

Indexed keywords

ATORVASTATIN; CHOLESTEROL; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 12P40; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL TYPE; CENTRAL NERVOUS SYSTEM; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOKINE RESPONSE; ENZYME ACTIVATION; INNATE IMMUNITY; MACROPHAGE; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PRENYLATION; RHESUS MONKEY; SIGNAL TRANSDUCTION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BONE MARROW; BRAIN; CELLS, CULTURED; CHOLESTEROL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MACACA MULATTA; MACROPHAGES; MICROGLIA; MYELOID DIFFERENTIATION FACTOR 88; PYRROLES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 2;

EID: 81155124445     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.21245     Document Type: Article

References (41)

1. Akira S. 2006. TLR signaling. Curr Top Microbiol Immunol 311: 1-16.
2. Bajramovic JJ. 2011. Regulation of innate immune responses in the central nervous system. CNS Neurol Disord Drug Targets 10: 4-24.
3. Bi X, Baudry M, Liu J, Yao Y, Fu L, Brucher F, Lynch G. 2004. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. J Biol Chem 279: 48238-48245.
4. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. 2008. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71: 1390-1395.
5. Bsibsi M, Ravid R, Gveric D, van Noort JM. 2002. Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 61: 1013-1021.
6. Cordle A, Landreth G. 2005. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses. J Neurosci 25: 299-307.
7. Goldstein JL, Brown MS. 1990. Regulation of the mevalonate pathway. Nature 343: 425-430.
8. Grip O, Janciauskiene S, Lindgren S. 2000. Pravastatin down-regulates inflammatory mediators in human monocytes in vitro. Eur J Pharmacol 410: 83-92.
9. Hodgkinson CP, Ye S. 2008. Statins inhibit Toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. Pharmacogenet Genomics 18: 803-813.
10. Jack CS, Arbour N, Manusow J, Montgrain V, Blain M, McCrea E, Shapiro A, Antel JP. 2005. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 175: 4320-30.
11. Janeway CAJr, Medzhitov R. 2002. Innate immune recognition. Annu Rev Immunol 20: 197-216.
12. Kawai T, Akira S. 2005. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 17: 338-344.
13. Klopfleisch S, Merkler D, Schmitz M, Kloppner S, Schedensack M, Jeserich G, Althaus HH, Bruck W. 2008. Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci 28: 13609-13614.
14. Konat GW, Krasowska-Zoladek A, Kraszpulski M. 2008. Statins enhance Toll-like receptor 4-mediated cytokine gene expression in astrocytes: Implication of Rho proteins in negative feedback regulation. J Neurosci Res 86: 603-609.
15. Kuipers HF, Biesta PJ, Groothuis TA, Neefjes JJ, Mommaas AM, van den Elsen PJ. 2005. Statins affect cell-surface expression of major histocompatibility complex class II molecules by disrupting cholesterol-containing microdomains. Hum Immunol 66: 653-665.
16. Kuipers HF, Rappert AA, Mommaas AM, van Haastert ES, van der Valk P, Boddeke HW, Biber KP, van den Elsen PJ. 2006. Simvastatin affects cell motility and actin cytoskeleton distribution of microglia. Glia 53: 115-123.
17. Kwak B, Mulhaupt F, Myit S, Mach F. 2000. Statins as a newly recognized type of immunomodulator. Nat Med 6: 1399-1402.
18. Lanzillo R, Orefice G, Quarantelli M, Rinaldi C, Prinster A, Ventrella G, Spitaleri D, Lus G, Vacca G, Carotenuto B, Salvatore E, Brunetti A, Tedeschi G, Brescia Morra V. 2010. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy. Mult Scler 16: 450-454.
19. Lindberg C, Crisby M, Winblad B, Schultzberg M. 2005. Effects of statins on microglia. J Neurosci Res 82: 10-19.
20. Matsumoto M, Einhaus D, Gold ES, Aderem A. 2004. Simvastatin augments lipopolysaccharide-induced proinflammatory responses in macrophages by differential regulation of the c-Fos and c-Jun transcription factors. J Immunol 172: 7377-7384.
21. Methe H, Kim JO, Kofler S, Nabauer M, Weis M. 2005. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 25: 1439-1445.
22. Miron VE, Zehntner SP, Kuhlmann T, Ludwin SK, Owens T, Kennedy TE, Bedell BJ, Antel JP. 2009. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 174: 1880-1890.
23. Neuhaus O, Strasser-Fuchs S, Fazekas F, Kieseier BC, Niederwieser G, Hartung HP, Archelos JJ. 2002. Statins as immunomodulators: Comparison with interferon-β 1b in MS. Neurology 59: 990-997.
24. Niessner A, Steiner S, Speidl WS, Pleiner J, Seidinger D, Maurer G, Goronzy JJ, Weyand CM, Kopp CW, Huber K, Wolzt M, Wojta J. 2006. Simvastatin suppresses endotoxin-induced upregulation of Toll-like receptors 4 and 2 in vivo. Atherosclerosis 189: 408-413.
25. O'Neill LA. 2006. How Toll-like receptors signal: What we know and what we don't know. Curr Opin Immunol 18: 3-9.
26. Olson JK, Miller SD. 2004. Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs. J Immunol 173: 3916-3924.
27. Pahan K, Sheikh FG, Namboodiri AM, Singh I. 1997. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 100: 2671-2679.
28. Paintlia AS, Paintlia MK, Singh I, Singh AK. 2008. Combined medication of lovastatin with rolipram suppresses severity of experimental autoimmune encephalomyelitis. Exp Neurol 214: 168-180.
29. Paintlia AS, Paintlia MK, Singh I, Skoff RB, Singh AK. 2009. Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis. Glia 57: 182-193.
30. Paul F, Waiczies S, Wuerfel J, Bellmann-Strobl J, Dorr J, Waiczies H, Haertle M, Wernecke KD, Volk HD, Aktas O, et al. 2008. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 3: e1928.
31. Pfaffl MW. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
32. Stanislaus R, Pahan K, Singh AK, Singh I. 1999. Amelioration of experimental allergic encephalomyelitis in Lewis rats by lovastatin. Neurosci Lett 269: 71-74.
33. Stuve O, Youssef S, Steinman L, Zamvil SS. 2003. Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 16: 393-401.
34. Takeda K. 2005. Toll-like receptor. Nihon Rinsho Meneki Gakkai Kaishi 28: 309-17.
35. Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M. 2010. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon β 1a: A double-blind randomized controlled trial. Mult Scler 16: 848-854.
36. Townsend KP, Shytle DR, Bai Y, San N, Zeng J, Freeman M, Mori T, Fernandez F, Morgan D, Sanberg P, Tan J. 2004. Lovastatin modulation of microglial activation via suppression of functional CD40 expression. J Neurosci Res 78: 167-176.
37. van der Putten C, Zuiderwijk-Sick EA, van Straalen L, de Geus ED, Boven LA, Kondova I, AP IJ, Bajramovic JJ. 2009. Differential expression of adenosine A3 receptors controls adenosine A2A receptor-mediated inhibition of TLR responses in microglia. J Immunol 182: 7603-7612.
38. Vollmer T, Key L, Durkalski V, Tyor W, Corboy J, Markovic-Plese S, Preiningerova J, Rizzo M, Singh I. 2004. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 363: 1607-1608.
39. Yilmaz A, Reiss C, Weng A, Cicha I, Stumpf C, Steinkasserer A, Daniel WG, Garlichs CD. 2006. Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 79: 529-538.
40. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchell DJ, Sobel RA, Steinman L, Zamvil SS. 2002. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420: 78-84.
41. Zuiderwijk-Sick EA, van der Putten C, Bsibsi M, Deuzing IP, de Boer W, Persoon-Deen C, Kondova I, Boven LA, van Noort JM, t Hart BA, et al. 2007. Differentiation of primary adult microglia alters their response to TLR8-mediated activation but not their capacity as APC. Glia 55: 1589-1600.